Kornimate/medical-research-clean huggingface dataset:
immune cells in patients with granulomatous mastitis

Conditions: Granulomatous Mastitis

Summary: granulomatous mastitis is a rare, chronic, benign inflammatory disease of the breast that plays a role in many varying etiologies, including infectious and non-infectious causes. etiological reasons were examined in various studies, but neither etiology nor definite criteria for diagnosis were found. our aim in this study is to examine the role of immunophenotyping in differentiating the etiology of granulomatous mastitis and using it as a prognostic marker.

granulomatous mastitis is a rare, chronic, benign inflammatory disease of the breast that plays a role in many varying aetiology, including infectious and non-infectious causes. this disease can clinically and radiographically mimic breast cancer, which can pose a diagnostic challenge as well as concern during evaluation. a nonspecific inflammatory response, 'granuloma' is defined as necrosis or infiltration of other inflammatory leukocytes, with or without mononuclear phagocyte collection. it is thought to be caused by infectious agents or foreign substances that activate the immune system, leading to granuloma formation. some of the known inflammatory etiologies of granulomatous mastitis are autoimmune diseases such as tuberculosis (most commonly caused by mycobacterium tuberculosis), sarcoidosis, fungal infection and granulomatosis with polyangiitis and giant cell arteritis. these diseases cannot be distinguished clinically, pathologically, and radiographically from idiopathic granulomatous mastitis.in this study, we aimed to investigate lymphocyte subtypes in patients with granulomatous mastitis and to evaluate the differences in cell populations and its usability as a predictive marker in diagnosis.

Eligibility criteria:
inclusion criteria: * patients with granulomatous mastitis exclusion criteria: * cancer patients * patients with known immunodeficiency * pregnancy * patient diagnosed with tuberculosis

Keywords: mastitis immunophenotyping flow-cytometry
immunogenicity of rsv vaccines in residents of long-term care facilities (ltcf)

Conditions: Respiratory Syncytial Virus (RSV)

Summary: this clinical trial is studying the newly licensed rsv vaccines in adults over age 60 years living in long-term care facilities (nursing homes) by comparing the immune response to their vaccine to adults over age 60 years living in the community.


Eligibility criteria:
inclusion criteria: * ≥60 years of age who live in skilled nursing facilities or reside independently in the community * life expectancy of \>6 months, as assessed by the investigator * able to sign informed consent or to provide consent via a legally authorized representative (lar) exclusion criteria: * history of a current immunosuppressive condition or receipt of chemotherapy or other immunosuppressive or cytotoxic therapy, including chronic prednisone use of ≥ 20 mg/day for more than 14 days within 3 months of study vaccination * history of hypersensitivity or reaction to any vaccine component * simultaneous administration of another vaccine (influenza, sars-cov-2) or within a 14-day window before or after intervention * previous receipt or intended receipt of an rsv vaccine outside the study * receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration. * documented rsv infection within 2 months prior to study intervention.
enhanced assistance during radiotherapy for unmet essential needs

Conditions: Bone Cancer; Brain Cancer; Colorectal Cancer; Esophagus Cancer; Lymphoma; Salivary Gland Cancer; Head and Neck Cancer; Liver Cancer; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Small Intestine Cancer; Stomach Cancer; Urinary Bladder Cancer; Anal Cancer; Blood Cancer; Breast Cancer; Cervical Cancer; Lung Cancer; Kidney Cancer; Penile Cancer; Skin Cancer; Testicular Cancer; Thyroid Cancer; Uterine Cancer; Vaginal Cancer; Vulvar Cancer

Summary: this is a prospective single-arm study of an enhanced assistance intervention for patients with unmet essential needs undergoing \>10 fractions of radiotherapy comparing delay-free completion of radiotherapy in study participants to historic controls.


Eligibility criteria:
inclusion criteria: * at least 18 years of age. * planned to receive or currently receiving a protracted course of curative-intent (neoadjuvant, definitive, or postoperative) radiotherapy. * for the purposes of this study, radiotherapy must consist of \>10 fractions (if radiotherapy not yet initiated) or \>15 additional fractions after the date of consent (if radiotherapy initiated prior to study consent). * be willing to undergo radiotherapy at the barnes-jewish hospital location. * indicate at least 1 unmet essential need, including food insecurity, transportation insecurity, housing instability, utility needs, childcare needs, or other financial insecurity. * accept a referral to and meet with a social worker. * have unmet essential needs that will not be able to be fully addressed by standard assistance. this determination can be made by the assigned social worker or by the patient after they meet with the social worker. * ability to understand and willingness to sign an irb approved written informed consent document. legally authorized representatives may sign and give informed consent on behalf of study participants. exclusion criteria: * planned or scheduled to undergo radiotherapy simulation more than 28 days from the date of consent. * admitted to the hospital and not expected to undergo \>10 fractions of radiotherapy as an outpatient. * undergoing treatment for anaplastic thyroid cancer. patients with anaplastic thyroid cancer have a relatively low likelihood of completing radiotherapy due to the aggressive disease course.

Keywords: financial assistance health-related social needs social determinants of health radiotherapy cancer
implementing prescriber-pharmacist collaborative care for evidence-based anticoagulant use

Conditions: Pulmonary Embolism; Venous Thromboembolism; Atrial Fibrillation

Summary: the researchers hypothesize that existing-prescription notifications directed to pharmacists are more likely to lead to a prescription change than existing-prescription notifications directed to prescribers. furthermore, the researchers hypothesize that the availability of a pharmacist referral option is associated with a higher rate of prescription changes for initial-prescription alerts that are directed to the prescriber at the time of initial-prescribing errors. findings from this project will establish a framework for implementing prescriber-pharmacist collaboration for high risk medications, including anticoagulants

please note that the 3rd and 4th outcome measures are conditional on the outcomes of the 1st and 2nd outcome measures respectively. please note that enrollment of 300 will provide sufficient power to study.

Eligibility criteria:
prescribers: inclusion criteria: * michigan medicine provider with prescribing privileges * providers in ambulatory care settings * prescribe doac to patients 18 years and older exclusion criteria: * providers in inpatient settings * providers who are members of the study team

Keywords: prescribing alerts anticoagulation
fetuin a in hashimoto thyroiditis

Conditions: Hashimoto Thyroiditis

Summary: fetuin-a levels are reported to be low as a negative acute phase reactant in systemical inflammatory situations. hashimoto thyroiditis is characterized with inflammation. in this study, we hypothesised that the serum fetuin a levels could be found to be low due to inflammation in patients with hashimoto thyroiditis

patients ≥ 20 years of age being followed up at the outpatient clinics of the internal medicine department in medeniyet university goztepe training and research hospital and fulfilling the eligibility criteria will be included in the study. approval of the local ethics committee and informed consent of the participants will be received for the study. the study is conducted in accordance with the declaration of helsinki. demographic characteristics, concomitant diseases, smoking and alcohol drinking habits, concomitant medication usage, anthropometric and biochemistry data of the eligible patients will be recorded. patient group will consist of patients with newly diagnosed hashimoto thyroiditis and the control group will consist of healthy volunteers. groups will be compared according to their demographic, an¬thropometric and biochemistry data and serum fetuin-a levels. in order to detect the relationship between the serum fetuin-a levels and clinical features, correlation analyses will be done.

Eligibility criteria:
inclusion criteria: * patients newly diagnosed with hashimoto thyroiditis exclusion criteria: * acute infection * acute or chronic inflammatory disease * anti-inflammatory treatment (non-steroidal anti-inflammatory, corticosteroids etc.) * hypoxic situations (chronic obstructive pulmonary disease etc.) * severe heart, kidney and liver disease * pregnancy * endocrine disorders * malignancy * usage of drug that affects thyroid hormone levels

Keywords: acute phase reactant, fetuin a, hashimoto thyroiditis
articaine vs dexmedetomidine supplemented articaine

Conditions: Renal Failure

Summary: the aim of this study to test efficacy of adding dexmedetomidine to articaine on sensory, motor and duration of analgesia during hemodialysis fistula creation under ultrasound guided supraclavicular block

adult fifty patient with chronic renal failure on hemodialysis, scheduled for arteriovenous fistula creation under ultrasound guided supraclavicular block. patients were randomly allocated in two group. the articaine group (group a) received 40 ml articaine hydrochloride 2% and articaine-dexmedetomidine group (group ad) received 40 ml. of articaine 2% mixed with dexmedetomidine (1micogram/kg)

Eligibility criteria:
inclusion criteria: * adult patient with chronic renal failure on hemodialysis scheduled for radiocephalic fistula creation exclusion criteria: * allergy to local anesthetics. * infection at the site of needle insertion. * those having international normalized ratio more than 1.5. * coagulopathy. * neuromuscular, or severe hepatic or severe pulmonary disease. * those having epilepsy. * patients who refused to participate.

Keywords: hemodialysis
punctal plug study to determine the safety and retention times of various lengths of canalicular stents in volunteers

Conditions: Healthy; Dry Eye

Summary: the purpose of this study was to determine the safety and retention times of two different lengths (10 mm and 20 mm) of the mini monoka canicular stent when inserted in the eye for up to three months in subjects with or without dry eye.

this study consisted of 6 visits conducted over a period of 3 months. at visit 1 (day 0), the canalicular stent was inserted. if the stent insertion failed, the subject was rescheduled for insertion at the day 2 visit. if the stent insertion was not successfully completed by the end of the day 2 visit, the subject was discontinued from the study. any subject who had the stent inserted but lost the stent (noticed or unnoticed) after the day 2 visit was considered to have completed the study.

Eligibility criteria:
inclusion criteria: * sign informed consent. * with or without dry eye. * willing to discontinue contact lenses during the study. * other protocol-defined inclusion criteria may apply. exclusion criteria: * chronic, recurrent, or severe inflammatory eye disease. * ocular trauma within the past 6 months. * ocular hypertension or glaucoma. * history of punctal plug/canalicular stent insertion. * other protocol-defined exclusion criteria may apply.

Keywords: dry eye tear duct punctal plug
effect of systemic antibiotic therapy on postoperative complications in patients undergoing wisdom teeth removal surgery.

Conditions: Third Molar Extraction Surgery

Summary: 59 medically healthy patients, who are scheduled for third molar extraction surgery and give informed consent for the trial, are operated using a split-mouth technique. one group of patients will be assigned to the test group (amoxilan) for the first surgery and to the control group (placebo) for the second surgery, and vice versa, according to randomisation. patients receive 8 capsules amoxilan or placebo (according to randomisation) perioperatively, and 6 capsules amoxilan/placebo per day for 3 days postoperativeley.


Eligibility criteria:
inclusion criteria: * symptom-free, bilaterally located third molars * medically healthy patient ≥ 16 years * no allergies/intolerances against the investigational product/placebo * informed consent exclusion criteria: * general contraindications to wisdom tooth extraction surgery * (former) heavy smoking * use of antibiotics within the last three months or patients requiring antibiotic treatment prior to surgery * (planned) pregnancy/lactating
bci and evaluation of visual and task performance in subjects with eye diseases

Conditions: Glaucoma; Macular Degeneration; Glaucoma Suspect; Optic Neuropathy; Retinal Degeneration; Visual Pathway Disorder

Summary: the purpose of this research study is to better understand the impact of visual impairment caused by different eye diseases on the ability to perform daily activities and compare it to that in patients without eye diseases.


Eligibility criteria:
inclusion criteria: * subjects must be between the ages of 18 and 90 years old; * both males and females will be included. * be able and willing to provide signed informed consent and follow study instructions exclusion criteria: * subjects will be excluded if they present with any systemic conditions that in the opinion of the principal investigator may prevent them from completing the tests.

Keywords: virtual reality glaucoma age related macular degeneration quality of life visual field optical coherence tomography brain-computer interface
effect of a natural health product on urinary estrogen metabolites

Conditions: Breast Cancer

Summary: the purpose of this study is to determine if a supplemental formula can beneficially alter the ratio of urinary estrogen metabolites.

the active botanical constituents in femmed breast health formula contain lignans, compounds with anti-estrogenic activity, that have been shown to exert an estrogenic effect during the follicular phase \[i.e. when estrogen is low\] and an antiestrogenic effect in the luteal phase of a female menstrual cycle. these are plant-derived chemicals that can act as weak mimics of estrogen in the body. overall these compounds have been found to be helpful in stabilizing the natural cyclical fluctuation of estrogen levels. the trial will be a double-blind, placebo-controlled parallel study in which 100 subjects will be recruited to one of two arms of the study: one arm will consist of pre-menopausal women; another will consist of post-menopausal women. each arm of the study will be carried out concurrently and in one phase, with no washout period. the placebo assignment will be randomized within each arm of the study. subjects in each arm of the study will follow the same protocol. urine and blood samples will be collected from each group at both the first and last visit, and subjects will receive a month's supply of treatment or placebo at the first visit, which they will consume on a daily basis until their second lab visit 28 days later. urine samples will be analyzed for the following estrogen metabolites: 2-oh-estrone and 16-α oh-estrone. blood samples would be collected and assessed for levels of enterolactone. pre and post-supplementation results will be assesses for any differences by statistical comparison.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * healthy * willing to collect urine samples and to have blood drawn * post-menopausal and have not taken hormone replacement therapy (hrt) in the past year (48 subjects) * pre-menopausal (48 subjects) exclusion criteria: * diagnosed with any major illness(e.g. cancer) * diabetes, thyroid disease, atypical hyperplasia, fibrocystic breast disease, family history of ovarian cancer, a history of "migraines with aura" * women taking blood thinner or thyroid medication (including warfarin) * known allergy to any of the any of the study ingredients * pregnancy or lactation * regular consumption in the previous 3 months of any other natural health products (nhps) or pharmaceutical containing ingredients with a similar effect on estrogen metabolism as those included in the femmed breast health treatment * family history of breast cancer risk * post-menopausal women on hrt * pre-menopausal women taking hormonal contraceptives (oral contraceptives, the patch etc.) * all other forms of estrogen, progesterone and/or androgens (i.e. testosterone therapy)

Keywords: urinary estrogen metabolites 2-oh estrone 16-alpha-oh estrone urinary 2/16a estrogen metabolite ratio
engaging partners in caring communities

Conditions: Chronic Disease Prevention

Summary: the goal of the epicc observational study is to learn about capacity to implement evidence-based health promotion programs (ebps) in congregations that are offered semi-structured technical assistance (ta). congregational teams will complete an implementation capacity assessment survey before the ta is offered and 10 months later, after ta has been provided for up to 10 months. participating congregations will be a convenience sample of congregations in davidson county, tn that serve primarily african american communities.

the recruitment process is designed to provide a team of 3-5 volunteers from 40 congregations with information about five ebps identified by the research team from which they are to choose one. the team completes one epicc survey for their congregation. the team is then offered up to 10 months of ta with the expectation that 2-3 months will be used for planning to launch the ebp, with 4-6 months for implementation. each congregation will be asked to recruit a minimum of 8-10 members of the congregation to complete a brief report of health behaviors prior to launching of the ebp and repeating that report 6 months later to assess the impact of the ebp on their health behaviors.

Eligibility criteria:
inclusion criteria: adult (18 years and older) participants in the behavioral intervention (implemented health promotion program) in a congregation in davidson county that has completed enrollment in the epicc project. exclusion criteria: * individuals who are not enrolled in a health promotion program implemented in an epicc congregation

Keywords: community-engaged research health equity health disparities implementation science faith-based organizations
capecitabine, docetaxel and gemcitabine in patients with advanced pancreas cancer

Conditions: Pancreatic Cancer

Summary: the primary purpose of this study is to define the maximum tolerated dose of combination docetaxel, gemcitabine, and capecitabine in patients with pancreatic cancer. adverse effects will be measured in study participants. in addition, researchers will assess data about preliminary efficacy in patients with this treatment approach.

rationale: single agent gemcitabine is considered standard care for patients with advanced pancreatic cancer. however, better treatments offering improved outcomes are needed for people with this disease. the combination of docetaxel and capecitabine has shown significant and broad clinical activity in a variety of tumors. laboratory research on the combination of capecitabine, docetaxel, and gemcitabine indicates synergistic action against tumor cells. the current study will test this combination in patients. the drug administration schedule in this study is aimed at maximizing the potential of activation of capecitabine by both docetaxel and gemcitabine. treatment: study participants will be given docetaxel, gemcitabine, and capecitabine. all study drugs will be administered through intravenous infusions in three week cycles. docetaxel will be given on days 1 and 8, gemcitabine on days 8 and 15, and capecitabine on days 8 through 21. this schedule will be followed by 1 week of rest without administration of study drugs. since the primary goal of this study is to identify the maximum tolerated dose of the study drugs in combination, patients who enroll in the beginning of the study will receive lower amounts of the study drugs compared to patients who enroll later in the study. several tests and exams will be given throughout the study to closely monitor patients.

Eligibility criteria:
inclusion criteria: * adenocarcinoma of the pancreas * no prior chemo except adjuvant * eastern cooperative oncology group (ecog) performance status 0-1 * peripheral neuropathy \</= gr. 1 exclusion criteria: * pregnant/lactating females * uncontrolled heart disease, diabetes, psychiatric disorder * therapeutic doses of warfarin

Keywords: advanced pancreatic cancer
hemodynamic study of in-stent stenosis(i) after flow diverter(f) based on 3d-dsa(d) combined with tccd(t)

Conditions: Hemodynamics;In-stent Stenosis;Transcranial Doppler;Intracranial Aneurysm;Flow Diverter; Prospective Cohort Study

Summary: dtfi is a single-center, prospective cohort study aimed at evaluating the hemodynamics of in-stent stenosis after flow diverter implantation, seeking to identify the threshold effect of blood flow in stenosis.

dtfi study investigates the hemodynamic changes in patients with intracranial aneurysms who have undergone flow diverter implantation, using a combination of three-dimensional digital subtraction angiography (3d-dsa) and transcranial color-coded duplex (tccd) sonography. the aim is to understand the development of in-stent stenosis and its impact on blood flow.

Eligibility criteria:
inclusion criteria: age ≥ 18, male or non-pregnant female. diagnosis of intracranial aneurysm confirmed by dsa (digital subtraction angiography). intracranial aneurysms treated with flow diverter (fd). dsa follow-up of at least 1 month. exclusion criteria: secondary intracranial aneurysm cases: traumatic aneurysms, infectious aneurysms, or aneurysms associated with arteriovenous malformations (avm) or vasculitis. previously treated recurrent aneurysm or target aneurysm with craniotomy clipping surgery or other endovascular interventions. aneurysms located at the distal end of the circle of willis where tccd (transcranial color-coded doppler) cannot be detected. known familial clustering history. expected survival less than 1 year. preoperative clinical assessment with mrs (modified rankin scale) score ≥ 3. known allergy or contraindication to antiplatelet drugs, anticoagulants, contrast agents, anesthetics, nitinol memory alloy, platinum-tungsten alloy, or platinum-iridium alloy. severe respiratory, hepatic, or renal disease (e.g., creatinine ≥ 3.0 mg/dl excluding dialysis) or coagulation disorders. undergoing major surgery (e.g., limb fracture fixation, tumor resection, major organ surgery, etc.) within 30 days prior to signing informed consent or planned within 60 days after signing informed consent. pregnant or lactating women, or women with a positive pregnancy test.

Keywords: hemodynamics.in-stent stenosis.transcranial doppler.intracranial aneurysm.flow diverter.prospective cohort study.mechanical thrombectomy